scholarly journals 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

The Lancet ◽  
2019 ◽  
Vol 393 (10191) ◽  
pp. 2591-2598 ◽  
Author(s):  
Xavier Pivot ◽  
Gilles Romieu ◽  
Marc Debled ◽  
Jean-Yves Pierga ◽  
Pierre Kerbrat ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Randomised Trial ◽  
Final Analysis ◽  
Open Label ◽  
Phase 3 ◽  
Adjuvant Trastuzumab ◽  
Open Label Phase

Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial

2014 ◽  
Vol 15 (9) ◽  
pp. 997-1006 ◽  
Author(s):  
Robert Coleman ◽  
David Cameron ◽  
David Dodwell ◽  
Richard Bell ◽  
Caroline Wilson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Early Breast Cancer ◽  
Open Label ◽  
Phase 3 ◽  
Efficacy Analysis ◽  
Open Label Phase

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

2021 ◽  
Vol 22 (4) ◽  
pp. 499-511 ◽  
Author(s):  
Eric P Winer ◽  
Oleg Lipatov ◽  
Seock-Ah Im ◽  
Anthony Goncalves ◽  
Eva Muñoz-Couselo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Phase

scholarly journals Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial

2017 ◽  
Vol 18 (9) ◽  
pp. 1211-1220 ◽  
Author(s):  
Marloes G M Derks ◽  
Erik J Blok ◽  
Caroline Seynaeve ◽  
Johan W R Nortier ◽  
Elma Meershoek-Klein Kranenbarg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Adjuvant Tamoxifen ◽  
Open Label ◽  
Phase 3 ◽  
Team 10

scholarly journals First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase 3 iLLUMINATE trial

Haematologica ◽  
2022 ◽  
Author(s):  
Carol Moreno ◽  
Richard Greil ◽  
Fatih Demirkan ◽  
Alessandra Tedeschi ◽  
Bertrand Anz ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Final Analysis ◽  
Lymphocytic Leukemia ◽  
Small Lymphocytic Lymphoma ◽  
First Line ◽  
Open Label ◽  
Phase 3 ◽  
First Line Therapy ◽  
Line Therapy ◽  
Open Label Phase

iLLUMINATE is a randomized, open-label phase 3 study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. Eligible patients were aged ≥65 years, or

Sign in / Sign up

Export Citation Format

Share Document